Investor Presentaiton

BRAVO Clinical Study 91 patient multi-centre study with simple and complex ventral hernias in United States Number of patients who completed 23 23 Product Name Category Hernia recurrence rate¹ Number of hernia recurrence¹ Follow up Ovitex (Aroa) Reinforced Tissue Matrix 2.6%² 2 Ovitex (Aroa) Reinforced Tissue Matrix 0% 2 follow up period Months 76 12 0 51 24 Phasix (CR Bard) Resorbable Synthetic Mesh 5% 5 95 12 Phasix (CR Bard) Resorbable Synthetic Mesh Phasix (CR Bard) Resorbable Synthetic Mesh Strattice (Lifecell) Biologic Matrix 12% 23% 22% 11 95 18 19 82 36 15 69 12 Strattice (Lifecell) Biologic Matrix 33% 33 67 24 1. The level of recurrence at 90 days, 12 & 24 months are key metrics and have major cost implications for surgeons, hospitals, payors and patients. 2. Hernia recurrence rate based on number of hernia recurrences reported in patients who completed follow up and patients who reported recurrent hernia before the specified follow up period. Other clinical literature and conference presentations were based on all patients treated including those who did not complete follow up. AROA™ • Data for first 50 patients at 24 months from BRAVO shows significantly better outcomes compared to market leaders • Full data for 24 months due H2 2021

View entire presentation